Advertisement

Pediatric Cardiology

, Volume 40, Issue 3, pp 668–670 | Cite as

Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy

  • Dorin Sumanaru
  • Loic Josseran
  • Aben Essid
  • Blaise Mbieleu
  • Isabelle Haegy
  • Jean BergouniouxEmail author
Case Report

Abstract

The longer survival of patients with Duchenne muscular dystrophy due to advances in clinical care has increased the incidence of Duchenne muscular dystrophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.

Keywords

Duchenne muscular dystrophy Levosimendan Acute heart failure 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

The authors assert that all procedures contributing to this work comply with the ethical standard of the relevant national guidelines on human experimentation (1988 Huriet Law and 2004 Public Health Policy Law) and with the Helsinki Declaration of 1975, as revised in 2008, and has been approved by the institutional committee Comité de Protection des Personnes Ile-de-France XI, Saint-Germain en Lay, France.

References

  1. 1.
    Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271–277CrossRefPubMedGoogle Scholar
  2. 2.
    Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H (1998) Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98:2141–2147CrossRefPubMedGoogle Scholar
  3. 3.
    Lunghetti S, Palmerini E, Urselli R et al (2011) Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J 18:532–537CrossRefPubMedGoogle Scholar
  4. 4.
    Morelli A, De Castro S, Teboul JL et al (2005) Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31:638–644CrossRefPubMedGoogle Scholar
  5. 5.
    Follath F, Cleland JG, Just H et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196–202CrossRefPubMedGoogle Scholar
  6. 6.
    Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT (2006) Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 98(12):1641–1645CrossRefPubMedGoogle Scholar
  7. 7.
    Antila S, Sundberg S, Lehtonen LA (2007) Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007;46(7):535–552 (Review)CrossRefPubMedGoogle Scholar
  8. 8.
    Lilleberg J, Ylönen V, Lehtonen L, Toivonen L (2004) The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 38(2):80–84CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Pediatric Intensive Care UnitHôpital Raymond-Poincaré, APHPGarchesFrance
  2. 2.Epidemiology DepartmentHôpital Raymond-Poincaré, APHPGarchesFrance
  3. 3.Versailles Saint Quentin en Yvelines UniversityVersaillesFrance
  4. 4.Réanimation et soins intensifs pédiatriquesHôpital universitaire Raymond Poincaré, AP-HPGarchesFrance

Personalised recommendations